Business Standard

Sunday, January 19, 2025 | 04:31 AM ISTEN Hindi

Notification Icon
userprofile IconSearch

Torrent Pharma Q3 PAT up 14% to Rs 249 crore riding on India, Brazil

Torrent Pharma's revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23

Torrent Pharmaceuticals
Premium

Torrent Pharma’s US revenues were up by 24 percent during the quarter to Rs 291 crore, while in constant currency terms it was up 13 percent.

Sohini Das Mumbai
Ahmedabad-based Torrent Pharmaceuticals posted a 14 per cent rise in net profit for the third quarter of the 2022-23 fiscal to Rs 249 crore on the back of good growth in the India and Brazil markets.

Torrent Pharma’s revenues came in at Rs 2,491 crore for the quarter under review. The Ebitda margins were at 29.1 per cent while gross margins were 71 per cent during Q3FY23.

India, Torrent’s key market, grew by 17 per cent to Rs 1,259 crore including revenues from the integration of its recently acquired outfit Curatio Healthcare (a dermatology firm). “Field force has been further expanded and

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in